CXCR2 and cancer: SX-682 significantly inhibits G-MDSCs trafficking without altering CXCR2 ligand expression.137 Preclinical studies have shown that the inhibition of G-MDSC trafficking by SX-682 enhances T-cell based immunotherapy, indicating a potential benefit against MDSC-infiltrated cancers.138 A study (NCT03161431) is being performed to determine whether SX-682 blocks MDSCs recruitment into tumors.